VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...
Pharmaceutical
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in...
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissueNo dose-limiting toxicities observed in...
BBS-Bioactive Bone Substitutes Oyj: The subscription period for the first warrant series starts on 21 November 2022 – the subscription price is EUR 0.92 per share
BBS-Bioactive Bone Substitutes Oyj, Company release, 18 November 2022 at 2.30 p.m. EET BBS-Bioactive Bone Substitutes Oyj (BBS) organized a...
BBS-Bioactive Bone Substitutes – Inside information: The first audit completed by the Notified Body, CE marking process may continue as planned
BBS-Bioactive Bone Substitutes Oyj, Company release, Inside Information, 18 November 2022 at 2.30 p.m. EET The Notified Body has completed...
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov....
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron...
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage,...
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
-Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via...
G1 Therapeutics Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and...
Theralase ® Closes Private Placement Equity Financing
TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
Syneos Health to Participate in Fireside Chat at the 2022 Evercore ISI HealthCONx Conference
MORRISVILLE, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced...
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage,...
Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today...
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with...
Beyond Air® To Participate in Piper’s 34th Annual Healthcare Conference
GARDEN CITY, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company...
G1 Therapeutics Announces Proposed Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class...